Temsirolimus (BioDeep_00000010491)
Secondary id: BioDeep_00000858820
human metabolite blood metabolite Chemicals and Drugs Volatile Flavor Compounds
代谢物信息卡片
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
化学式: C56H87NO16 (1029.6024542)
中文名称: 替西罗莫司
谱图信息:
最多检出来源 Homo sapiens(blood) 50%
分子结构信息
SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC
InChI: InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
描述信息
Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EG - Mammalian target of rapamycin (mtor) kinase inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents > D000091203 - MTOR Inhibitors
Same as: D06068
Temsirolimus is an inhibitor of mTOR with an IC50 of 1.76 μM. Temsirolimus activates autophagy and prevents deterioration of cardiac function in animal model[8].
Temsirolimus is an inhibitor of mTOR with an IC50 of 1.76 μM. Temsirolimus activates autophagy and prevents deterioration of cardiac function in animal model[8].
同义名列表
10 个代谢物同义名
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate; 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoic acid]rapamycin; Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Wyeth brand OF temsirolimus; Temsirolimus; CCI-779; Torisel; CCI 779; Temsirolimus
数据库引用编号
19 个数据库交叉引用编号
- ChEBI: CHEBI:79699
- KEGG: C15182
- PubChem: 23724530
- PubChem: 6918289
- PubChem: 148191
- HMDB: HMDB0015632
- Metlin: METLIN70671
- DrugBank: DB06287
- ChEMBL: CHEMBL1201182
- Wikipedia: Temsirolimus
- chemspider: 21468899
- CAS: 162635-04-3
- PMhub: MS000024355
- PubChem: 17396179
- PDB-CCD: A4I
- NIKKAJI: J1.737.432J
- RefMet: Temsirolimus
- medchemexpress: HY-50910
- KNApSAcK: 79699
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Arne Strauss, Marianne Schmid, Michael Rink, Michael Moran, Stephan Bernhardt, Marcus Hubbe, Lothar Bergmann, Katrin Schlack, Martin Boegemann. Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry.
Future oncology (London, England).
2021 Jun; 17(18):2325-2338. doi:
10.2217/fon-2020-1020. [PMID: 33724867] - Hiromasa Sakamoto, Toshinari Yamasaki, Takayuki Sumiyoshi, Masashi Takeda, Noboru Shibasaki, Noriaki Utsunomiya, Ryuichiro Arakaki, Shusuke Akamatsu, Takashi Kobayashi, Takahiro Inoue, Tomomi Kamba, Eijiro Nakamura, Osamu Ogawa. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.
Cancer medicine.
2021 01; 10(1):119-134. doi:
10.1002/cam4.3578. [PMID: 33107222] - Annemarie Uhlig, Johannes Uhlig, Lutz Trojan, Michael Woike, Marianne Leitsmann, Arne Strauß. Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer.
Future oncology (London, England).
2021 Jan; 17(1):45-56. doi:
10.2217/fon-2020-0900. [PMID: 33275038] - Fabian Hofmann, Eu Chang Hwang, Thomas Bl Lam, Axel Bex, Yuhong Yuan, Lorenzo So Marconi, Börje Ljungberg. Targeted therapy for metastatic renal cell carcinoma.
The Cochrane database of systematic reviews.
2020 10; 10(?):CD012796. doi:
10.1002/14651858.cd012796.pub2. [PMID: 33058158] - Nizar M Tannir, Pavlos Msaouel, Jeremy A Ross, Catherine E Devine, Anuradha Chandramohan, Graciela M Nogueras Gonzalez, Xuemei Wang, Jennifer Wang, Paul G Corn, Zita D Lim, Lisa Pruitt, Jose A Karam, Christopher G Wood, Amado J Zurita. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
European urology oncology.
2020 10; 3(5):687-694. doi:
10.1016/j.euo.2019.06.004. [PMID: 31272939] - Sen Chen, Long Cui, Qiao Hu, Yingying Shen, Yan Jiang, Juan Zhao. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
Biochemical and biophysical research communications.
2020 09; 530(1):142-148. doi:
10.1016/j.bbrc.2020.06.133. [PMID: 32828276] - Shigeru Sugiyama, Kazuo Sato, Yoshiyuki Shibasaki, Yutaka Endo, Taku Uryu, Yasuharu Toyoshima, Mototsugu Oya, Naoto Miyanaga, Nagahiro Saijo, Akihiko Gemma, Hideyuki Akaza. Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study.
Japanese journal of clinical oncology.
2020 Aug; 50(8):940-947. doi:
10.1093/jjco/hyaa062. [PMID: 32458996] - Yuqing Li, Yanyun Shen, Zhidong Zhu, Hui Wen, Chenchen Feng. Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.
Cancer medicine.
2020 08; 9(16):6020-6029. doi:
10.1002/cam4.3281. [PMID: 32628820] - Kazuki Kuroshima, Hirofumi Yoshino, Shunsuke Okamura, Masafumi Tsuruda, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Shuichi Tatarano, Masayuki Nakagawa, Hideki Enokida. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Cancer science.
2020 May; 111(5):1607-1618. doi:
10.1111/cas.14395. [PMID: 32232883] - Yukari Kobayashi, Daisuke Yamada, Taketo Kawai, Yusuke Sato, Taro Teshima, Yuta Yamada, Masaaki Nakamura, Motofumi Suzuki, Akihiko Matsumoto, Tohru Nakagawa, Akihiro Hosoi, Koji Nagaoka, Takahiro Karasaki, Hirokazu Matsushita, Haruki Kume, Kazuhiro Kakimi. Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma.
International journal of oncology.
2020 04; 56(4):999-1013. doi:
10.3892/ijo.2020.4975. [PMID: 32319571] - Juan M Roldan-Romero, Benoit Beuselinck, María Santos, Juan F Rodriguez-Moreno, Javier Lanillos, Bruna Calsina, Ana Gutierrez, Karin Tang, Nuria Lainez, Javier Puente, Daniel Castellano, Emilio Esteban, Miguel A Climent, Jose A Arranz, Maarten Albersen, Stephane Oudard, Gabrielle Couchy, Eduardo Caleiras, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, Cristina Rodríguez-Antona, Jesús García-Donas. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
International journal of cancer.
2020 03; 146(5):1435-1444. doi:
10.1002/ijc.32579. [PMID: 31335987] - Po-Ming Chow, Shing-Hwa Liu, Yu-Wei Chang, Kuan-Lin Kuo, Wei-Chou Lin, Kuo-How Huang. The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma.
Cancer letters.
2020 02; 471(?):27-37. doi:
10.1016/j.canlet.2019.12.005. [PMID: 31812697] - Ravneet Chhabra, Meera Nanjundan. Lysophosphatidic acid reverses Temsirolimus-induced changes in lipid droplets and mitochondrial networks in renal cancer cells.
PloS one.
2020; 15(6):e0233887. doi:
10.1371/journal.pone.0233887. [PMID: 32492043] - Lothar Bergmann, Viktor Grünwald, Luise Maute, Marc-Oliver Grimm, Steffen Weikert, Jan Schleicher, Theodor Klotz, Jochen Greiner, Anne Flörcken, Arndt Hartmann, Thomas Gauler. A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society.
Oncology research and treatment.
2020; 43(7-8):333-339. doi:
10.1159/000508450. [PMID: 32541143] - Zhiping Yu, Yixuan Wang, Dan Xu, Lianhua Zhu, Ming Hu, Qiuli Liu, Weihua Lan, Jun Jiang, Luofu Wang. G250 Antigen-Targeting Drug-Loaded Nanobubbles Combined with Ultrasound Targeted Nanobubble Destruction: A Potential Novel Treatment for Renal Cell Carcinoma.
International journal of nanomedicine.
2020; 15(?):81-95. doi:
10.2147/ijn.s230879. [PMID: 32021166] - In Hee Lee, Byung Woog Kang, Jong Gwang Kim, Woo Kyun Bae, Myung Seo Ki, Inkeun Park, Jae-Cheol Jo, Jin Young Kim, Sung Ae Koh, Kyung Hee Lee, Yoon Young Cho, Hun Mo Ryoo, Sang Gyu Kwak, Jung Lim Lee, Sun Ah Lee. Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy.
The Korean journal of internal medicine.
2020 01; 35(1):185-193. doi:
10.3904/kjim.2018.064. [PMID: 30301310] - Orsolya Basa-Dénes, Réka Angi, Balázs Kárpáti, Tamás Jordán, Zsolt Ötvös, Nikoletta Erdősi, Andrea Ujhelyi, Betti Ordasi, László Molnár, John McDermott, Chris Roe, Litza McKenzie, Tamás Solymosi, Gábor Heltovics, Hristos Glavinas. Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers.
European journal of drug metabolism and pharmacokinetics.
2019 Dec; 44(6):777-785. doi:
10.1007/s13318-019-00562-y. [PMID: 31089971] - Sherrie L Aspinall, Xinhua Zhao, Mark C Geraci, Chester B Good, Francesca E Cunningham, Bernadette B Heron, Daniel Becker, Steve Lee, Vinay Prasad. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration.
Cancer medicine.
2019 11; 8(15):6651-6661. doi:
10.1002/cam4.2531. [PMID: 31536684] - Nikolina Basic-Jukic, Ines Mesar, Jason Kirincich. Cutaneous Metastasis as a Presenting Feature of Renal Adenocarcinoma in a Renal Transplant Recipient: A Case Report.
Transplantation proceedings.
2019 Nov; 51(9):3072-3073. doi:
10.1016/j.transproceed.2019.04.021. [PMID: 31611123] - Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha. Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma.
Cancer research and treatment.
2019 Oct; 51(4):1578-1588. doi:
10.4143/crt.2018.671. [PMID: 30999721] - Niels Fristrup, Frede Donskov. Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study.
Clinical genitourinary cancer.
2019 08; 17(4):254-259. doi:
10.1016/j.clgc.2019.03.023. [PMID: 31101577] - Jiangjin Li, Xiaoli Xiang, Zuo Xu. Cilostazol protects against myocardial ischemia and reperfusion injury by activating transcription factor EB (TFEB).
Biotechnology and applied biochemistry.
2019 Jul; 66(4):555-563. doi:
10.1002/bab.1754. [PMID: 30994947] - Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, Jae Lyun Lee. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.
BMC urology.
2019 Jun; 19(1):51. doi:
10.1186/s12894-019-0484-2. [PMID: 31182090] - Julie Bastin, Emilie Werbrouck, Annelies Verbiest, Kevin Punie, Oliver Bechter, Feng Jung Woei-A-Jin, Pascal Wolter, Hans Wildiers, Evelyne Lerut, Herlinde Dumez, Brigitte Decallonne, Paul Clement, Dirk Vanderschueren, Maarten Albersen, Raymond Oyen, Patrick Schöffski, Benoit Beuselinck. Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.
Acta clinica Belgica.
2019 Jun; 74(3):169-179. doi:
10.1080/17843286.2018.1476115. [PMID: 29774795] - Aristotelis Bamias, Vasilios Karavasilis, Nikolaos Gavalas, Kimon Tzannis, Epaminontas Samantas, Gerasimos Aravantinos, Angelos Koutras, Ioannis Gkerzelis, Euthymios Kostouros, Konstantinos Koutsoukos, Flora Zagouri, George Fountzilas, Meletios-Athanasios Dimopoulos. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
International journal of clinical oncology.
2019 Apr; 24(4):411-419. doi:
10.1007/s10147-018-1361-9. [PMID: 30374686] - So-Yeon Jeon, Na-Ri Lee, Chang-Yeol Yim. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
BMC nephrology.
2019 01; 20(1):1. doi:
10.1186/s12882-018-1181-1. [PMID: 30606155] - Lana Hamieh, Toni K Choueiri, Barbara Ogórek, Damir Khabibullin, Daniel Rosebrock, Dimitri Livitz, Andre Fay, Jean-Christophe Pignon, David F McDermott, Neeraj Agarwal, Wenhua Gao, Sabina Signoretti, David J Kwiatkowski. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
PLoS genetics.
2018 09; 14(9):e1007679. doi:
10.1371/journal.pgen.1007679. [PMID: 30256787] - Anas Shamsi, Azaj Ahmed, Bilqees Bano. Probing the interaction of anticancer drug temsirolimus with human serum albumin: molecular docking and spectroscopic insight.
Journal of biomolecular structure & dynamics.
2018 May; 36(6):1479-1489. doi:
10.1080/07391102.2017.1326320. [PMID: 28464730] - Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, Cristina Rodríguez-Antona. Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.
Journal of the National Comprehensive Cancer Network : JNCCN.
2018 04; 16(4):352-358. doi:
10.6004/jnccn.2017.7041. [PMID: 29632054] - Anas Shamsi, Azaj Ahmed, Bilqees Bano. Global transition of human serum albumin to prefibrillar aggregates induced by temsirolimus: Insight into implications of anti-renal cancer drug.
Journal of molecular recognition : JMR.
2018 04; 31(4):. doi:
10.1002/jmr.2688. [PMID: 29178153] - Minsoo Song. Recent developments in small molecule therapies for renal cell carcinoma.
European journal of medicinal chemistry.
2017 Dec; 142(?):383-392. doi:
10.1016/j.ejmech.2017.08.007. [PMID: 28844802] - Ashutosh Chauhan, Rani Ojha, Deepak K Semwal, Satyendra P Mishra, Ruchi B Semwal. Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway.
Anti-cancer agents in medicinal chemistry.
2017 Nov; 17(11):1545-1554. doi:
10.2174/1871520617666170213111002. [PMID: 28270077] - Juan Francisco Rodríguez-Moreno, María Apellaniz-Ruiz, Juan María Roldan-Romero, Ignacio Durán, Luis Beltrán, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, Jesus García-Donas, Cristina Rodríguez-Antona. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation.
Journal of the National Comprehensive Cancer Network : JNCCN.
2017 11; 15(11):1310-1315. doi:
10.6004/jnccn.2017.7018. [PMID: 29118224] - Mamta Singla, Shalmoli Bhattacharyya. Autophagy as a potential therapeutic target during epithelial to mesenchymal transition in renal cell carcinoma: An in vitro study.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2017 Oct; 94(?):332-340. doi:
10.1016/j.biopha.2017.07.070. [PMID: 28772211] - Maeva Dufies, Sandy Giuliano, Julien Viotti, Delphine Borchiellini, Linsay S Cooley, Damien Ambrosetti, Mélanie Guyot, Papa Diogop Ndiaye, Julien Parola, Audrey Claren, Renaud Schiappa, Jocelyn Gal, Antoine Frangeul, Arnaud Jacquel, Ophélie Cassuto, Renaud Grépin, Patrick Auberger, Andréas Bikfalvi, Gérard Milano, Bernard Escudier, Nathalie Rioux-Leclercq, Camillo Porta, Sylvie Negrier, Emmanuel Chamorey, Jean-Marc Ferrero, Gilles Pagès. CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
British journal of cancer.
2017 Sep; 117(7):947-953. doi:
10.1038/bjc.2017.276. [PMID: 28850564] - Mizuho Akahane, Masakazu Nakashima, Hiromasa Sakamoto, Teruyoshi Aoyama, Jun Kawai. [A Case Report : Metastatic Carcinoma of the Collecting Ducts of Bellini in a Hemodialysis Patient Treated with Temsirolimus].
Hinyokika kiyo. Acta urologica Japonica.
2017 Jun; 63(6):239-243. doi:
10.14989/actauroljap_63_6_239. [PMID: 28694417] - Christos E Kyriakopoulos, Amy M Braden, Jill M Kolesar, Jens C Eickhoff, Howard H Bailey, Jennifer Heideman, Glenn Liu, Kari B Wisinski. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Investigational new drugs.
2017 06; 35(3):290-297. doi:
10.1007/s10637-016-0418-8. [PMID: 28004284] - Anant Ramaswamy, Amit Joshi, Vanita Noronha, Vijay M Patil, Rushabh Kothari, Arvind Sahu, Ram Abhinav Kannan, Nilesh Sable, Palak Popat, Santosh Menon, Kumar Prabhash. Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Clinical genitourinary cancer.
2017 06; 15(3):e345-e355. doi:
10.1016/j.clgc.2016.09.006. [PMID: 28077238] - Norbert Marschner, Lothar Müller, Axel Münch, Klaus Blumenstengel, Ulrich Hutzschenreuter, Sabine Busies. Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2017 Jun; 23(4):288-295. doi:
10.1177/1078155216632379. [PMID: 26908232] - Susanne Unverzagt, Ines Moldenhauer, Monika Nothacker, Dorothea Roßmeißl, Andreas V Hadjinicolaou, Frank Peinemann, Francesco Greco, Barbara Seliger. Immunotherapy for metastatic renal cell carcinoma.
The Cochrane database of systematic reviews.
2017 05; 5(?):CD011673. doi:
10.1002/14651858.cd011673.pub2. [PMID: 28504837] - Takatsugu Okegawa, Megumi Morimoto, Satoru Nishizawa, Satoshi Kitazawa, Kohei Honda, Hideo Araki, Toshiya Tamura, Ayumi Ando, Yoshinori Satomi, Kikuo Nutahara, Takahito Hara. Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors.
EBioMedicine.
2017 May; 19(?):31-38. doi:
10.1016/j.ebiom.2017.04.009. [PMID: 28408240] - Samara L Potter, Rajkumar Venkatramani, Scott Wenderfer, Brett H Graham, Sanjeev A Vasudevan, Andrew Sher, Hao Wu, David A Wheeler, Yaping Yang, Christine M Eng, Richard A Gibbs, Angshumoy Roy, Sharon E Plon, D Williams Parsons. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia.
Pediatric blood & cancer.
2017 05; 64(5):. doi:
10.1002/pbc.26286. [PMID: 27748010] - Keiji Ogari, Yukiyasu Arakawa, Zaigen Cho, Makoto Wada, Hideya Takenaka, Norito Katoh, Jun Asai. Subcutaneous fat necrosis due to molecular-targeted therapy.
The Journal of dermatology.
2017 Mar; 44(3):e7-e8. doi:
10.1111/1346-8138.13500. [PMID: 27374634] - Anas Shamsi, Azaj Ahmed, Bilqees Bano. Temsirolimus induced structural transition of cancerous renal cystatin to normal form in rats: In vitro mechanistic approach underlying renal cancer prevention.
International journal of biological macromolecules.
2017 Mar; 96(?):19-25. doi:
10.1016/j.ijbiomac.2016.12.019. [PMID: 27979728] - Sergio Fernández-Pello, Fabian Hofmann, Rana Tahbaz, Lorenzo Marconi, Thomas B Lam, Laurence Albiges, Karim Bensalah, Steven E Canfield, Saeed Dabestani, Rachel H Giles, Milan Hora, Markus A Kuczyk, Axel S Merseburger, Thomas Powles, Michael Staehler, Alessandro Volpe, Börje Ljungberg, Axel Bex. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
European urology.
2017 03; 71(3):426-436. doi:
10.1016/j.eururo.2016.11.020. [PMID: 27939075] - Do Hyoung Lim, Soon Il Lee, Keon Woo Park. Dystrophic calcification after palliative chemotherapy in a patient with renal cell carcinoma.
The Korean journal of internal medicine.
2017 03; 32(2):380-381. doi:
10.3904/kjim.2015.317. [PMID: 28049213] - M Dos Santos, P E Brachet, C Chevreau, F Joly. Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit.
Cancer treatment reviews.
2017 Feb; 53(?):53-60. doi:
10.1016/j.ctrv.2016.12.003. [PMID: 28073101] - M Jebali, R Elaidi, M Brizard, J Fouque, C Takouchop, B Sabatier, S Oudard, J Medioni. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
BMC cancer.
2017 01; 17(1):27. doi:
10.1186/s12885-016-2993-7. [PMID: 28061764] - Ilya Tsimafeyeu. Management of non-clear cell renal cell carcinoma: Current approaches.
Urologic oncology.
2017 01; 35(1):5-13. doi:
10.1016/j.urolonc.2016.07.011. [PMID: 27544302] - Viktor Grünwald, Xun Lin, Daniel Kalanovic, Ronit Simantov. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
European urology.
2016 12; 70(6):1006-1015. doi:
10.1016/j.eururo.2016.05.010. [PMID: 27238653] - Yuting Fu, Xu Zheng, Xiaoyang Jia, Uyanga Binderiya, Yanfeng Wang, Wenlei Bao, Lili Bao, Keyu Zhao, Yu Fu, Huifang Hao, Zhigang Wang. A quantitative transcriptomic analysis of the physiological significance of mTOR signaling in goat fetal fibroblasts.
BMC genomics.
2016 11; 17(1):879. doi:
10.1186/s12864-016-3151-y. [PMID: 27821074] - Mohmad Hussain Mir, Khalid Hamid Changal, Shiekh Aejaz Aziz, Gull Mohammad Bhat, Abdul Rashid Lone. Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?.
International urology and nephrology.
2016 Nov; 48(11):1811-1816. doi:
10.1007/s11255-016-1380-2. [PMID: 27448573] - Ivan Levakov, Sasa Vojinov, Goran Marusic, Milan Popov, Olivera Levakov, Mladen Popov, Dimitrije Jeremic. Safety profile of temsirolimus in patients with metastatic renal cell carcinoma.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
2016 Nov; 21(6):1442-1448. doi:
. [PMID: 28039705] - Emiliano Calvo, Manuela Schmidinger, Daniel Y C Heng, Viktor Grünwald, Bernard Escudier. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Cancer treatment reviews.
2016 Nov; 50(?):109-117. doi:
10.1016/j.ctrv.2016.09.002. [PMID: 27664394] - Andika Afriansyah, Agus Rizal Ah Hamid, Chaidir A Mochtar, Rainy Umbas. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Acta medica Indonesiana.
2016 Oct; 48(4):335-347. doi:
. [PMID: 28143997] - Daniel Patschan, Katrin Schwarze, Elvira Henze, Susann Patschan, Gerhard Anton Müller. Endothelial autophagy and Endothelial-to-Mesenchymal Transition (EndoMT) in eEPC treatment of ischemic AKI.
Journal of nephrology.
2016 Oct; 29(5):637-44. doi:
10.1007/s40620-015-0222-0. [PMID: 26289253] - Marin Golčić, Marija Petković. Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker?.
Medical hypotheses.
2016 Sep; 94(?):148-50. doi:
10.1016/j.mehy.2016.07.015. [PMID: 27515221] - Sung Han Kim, Sohee Kim, Jungnam Joo, Ho Kyung Seo, Jae Young Joung, Kang Hyun Lee, Jinsoo Chung. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
BMC cancer.
2016 08; 16(?):577. doi:
10.1186/s12885-016-2615-4. [PMID: 27484254] - Kathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, Jiaxi Song, Ingrid Carvo, Su-Chun Cheng, Mekailah Simpson, André P Fay, Igor Puzanov, M Dror Michaelson, Michael B Atkins, David F McDermott, Sabina Signoretti, Toni K Choueiri. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
Clinical genitourinary cancer.
2016 08; 14(4):304-313.e6. doi:
10.1016/j.clgc.2016.02.007. [PMID: 27036973] - Robert E Brown, Jamie Buryanek, Varaha S Tammisetti, Mary F McGuire, Keri Csencsits-Smith. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
Oncotarget.
2016 Jul; 7(27):41612-41621. doi:
10.18632/oncotarget.9508. [PMID: 27223432] - Shweta Takyar, Jose Diaz, Manu Sehgal, Francisco Sapunar, Hardev Pandha. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Anti-cancer drugs.
2016 Jun; 27(5):383-97. doi:
10.1097/cad.0000000000000335. [PMID: 26886011] - Olivia Le Saux, Gilles Freyer, Sylvie Négrier. First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.
Clinical drug investigation.
2016 May; 36(5):389-99. doi:
10.1007/s40261-016-0384-0. [PMID: 26945986] - Shiven B Patel, David D Stenehjem, David M Gill, Srinivas K Tantravahi, Archana M Agarwal, JoAnne Hsu, Winston Vuong, Sumanta K Pal, Neeraj Agarwal. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Clinical genitourinary cancer.
2016 Apr; 14(2):153-9. doi:
10.1016/j.clgc.2015.12.011. [PMID: 26781820] - D L Stanculeanu, A Lazescu, D D Zob, R Bunghez, R Anghel, T D Poteca. Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
Journal of medicine and life.
2016 Apr; 9(2):193-8. doi:
. [PMID: 27453754] - Shigeru Hashimoto, Shuji Mikami, Hirokazu Sugino, Ayumu Yoshikawa, Ari Hashimoto, Yasuhito Onodera, Shotaro Furukawa, Haruka Handa, Tsukasa Oikawa, Yasunori Okada, Mototsugu Oya, Hisataka Sabe. Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Nature communications.
2016 Feb; 7(?):10656. doi:
10.1038/ncomms10656. [PMID: 26854204] - Camillo Porta, Giampaolo Tortora, James M G Larkin, Thomas E Hutson. Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.
Future oncology (London, England).
2016 Feb; 12(4):533-49. doi:
10.2217/fon.15.313. [PMID: 26606910] - J D Rebibo, C Pfister, A Giwerc, G Defortescu, S Gouerant, F Di Fiore, F-X Nouhaud. [Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
2016 Jan; 26(1):16-23. doi:
10.1016/j.purol.2015.09.007. [PMID: 26455779] - Maria Giuseppa Vitale, Giacomo Cartenì. Clinical management of metastatic kidney cancer: the role of new molecular drugs.
Future oncology (London, England).
2016 Jan; 12(1):83-93. doi:
10.2217/fon.15.283. [PMID: 26617188] - Aaron P Mitchell, Michael R Harrison, Mark S Walker, Daniel J George, Amy P Abernethy, Bradford R Hirsch. Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
Journal of oncology practice.
2015 Nov; 11(6):491-7. doi:
10.1200/jop.2015.004929. [PMID: 26330533] - P Ivanyi, V Grünwald. [Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Aktuelle Urologie.
2015 Nov; 46(6):467-72. doi:
10.1055/s-0041-106136. [PMID: 26556569] - Elodie Jobard, Ellen Blanc, Sylvie Négrier, Bernard Escudier, Gwenaelle Gravis, Christine Chevreau, Bénédicte Elena-Herrmann, Olivier Trédan. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.
British journal of cancer.
2015 Oct; 113(8):1148-57. doi:
10.1038/bjc.2015.322. [PMID: 26372698] - NULL. Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
Annals of the Academy of Medicine, Singapore.
2015 Oct; 44(10):406-14. doi:
NULL. [PMID: 26763058] - X F Cheng, Q Liu, X F Zhang, H D Zhao, W Wang, A J Chu. Expression of mTOR and its inhibitory effect on cell proliferation and apoptosis of breast cancer cells.
Journal of biological regulators and homeostatic agents.
2015 Oct; 29(4):869-73. doi:
". [PMID: 26753650] - Anne V Soerensen, Frede Donskov, Jakob Kjellberg, Rikke Ibsen, Gregers G Hermann, Niels V Jensen, Kirsten Fode, Poul F Geertsen. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
European urology.
2015 Sep; 68(3):516-22. doi:
10.1016/j.eururo.2014.12.017. [PMID: 25533417] - François-Xavier Nouhaud, Christian Pfister, Guillaume Defortescu, Anthony Giwerc, David Charbit, Sophie Gouerant, Jean-Christophe Sabourin, Frédéric Di Fiore. Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Anti-cancer drugs.
2015 Sep; 26(8):866-71. doi:
10.1097/cad.0000000000000253. [PMID: 26020808] - Lorel Huelsmann, D Nathan W Kim, Raquibul Hannan, Lori M Watumull, James Brugarolas. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Clinical genitourinary cancer.
2015 Aug; 13(4):e321-e323. doi:
10.1016/j.clgc.2014.12.007. [PMID: 25620636] - Masahiro Nozawa, Takayuki Ohzeki, Satoshi Tamada, Fumiya Hongo, Satoshi Anai, Kiyohide Fujimoto, Tsuneharu Miki, Tatsuya Nakatani, Satoshi Fukasawa, Hirotsugu Uemura. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
International journal of clinical oncology.
2015 Aug; 20(4):790-5. doi:
10.1007/s10147-014-0764-5. [PMID: 25342378] - Siraj M Ali, Philip J Stephens, Vincent A Miller, Jeffrey S Ross, Sumanta Kumar Pal. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
European urology.
2015 Aug; 68(2):341-3. doi:
10.1016/j.eururo.2015.03.002. [PMID: 25796537] - Katharina John, Imme Rösner, Ulrich Keilholz, Thomas Gauler, Heike Bantel, Viktor Grünwald. Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients.
European journal of cancer (Oxford, England : 1990).
2015 Aug; 51(12):1596-602. doi:
10.1016/j.ejca.2015.05.021. [PMID: 26048456] - Keith T Flaherty, Judith B Manola, Michael Pins, David F McDermott, Michael B Atkins, Janice J Dutcher, Daniel J George, Kim A Margolin, Robert S DiPaola. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015 Jul; 33(21):2384-91. doi:
10.1200/jco.2015.60.9727. [PMID: 26077237] - Nicholas J Vogelzang, Michelle D Hackshaw, Thomas E Hutson, Debajyoti Bhowmik, Mark Yap, Debra Rembert, Eric Jonasch. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Clinical genitourinary cancer.
2015 Jun; 13(3):210-7. doi:
10.1016/j.clgc.2014.11.001. [PMID: 25498215] - Matthew T Campbell, Randall E Millikan, Emre Altinmakas, Lianchun Xiao, Sin Jen Wen, Arlene O Siefker-Radtke, Ana Aparicio, Paul G Corn, Nizar M Tannir. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
Clinical genitourinary cancer.
2015 Jun; 13(3):218-24. doi:
10.1016/j.clgc.2014.10.004. [PMID: 25465491] - Jennifer S Carew, Claudia M Espitia, Weiguo Zhao, Monica M Mita, Alain C Mita, Steffan T Nawrocki. Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.
Molecular cancer therapeutics.
2015 Jun; 14(6):1404-13. doi:
10.1158/1535-7163.mct-14-1036. [PMID: 25808836] - Josefin Axelsson, Anna Rippe, Bengt Rippe. mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside.
American journal of physiology. Renal physiology.
2015 May; 308(10):F1056-64. doi:
10.1152/ajprenal.00632.2014. [PMID: 25740597] - Inkeun Park, Jae-Lyun Lee, Jin-Hee Ahn, Dae-Ho Lee, Kyoo-Hyung Lee, Dalsan You, In Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
Cancer chemotherapy and pharmacology.
2015 May; 75(5):1025-35. doi:
10.1007/s00280-015-2725-8. [PMID: 25776906] - Roberto Iacovelli, Matteo Santoni, Elena Verzoni, Paolo Grassi, Isabella Testa, Filippo de Braud, Stefano Cascinu, Giuseppe Procopio. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.
Clinical genitourinary cancer.
2015 Apr; 13(2):137-41. doi:
10.1016/j.clgc.2014.07.006. [PMID: 25160521] - Jaime R Merchan, Rui Qin, Henry Pitot, Joel Picus, Glenn Liu, Tom Fitch, William J Maples, Patrick J Flynn, Briant F Fruth, Charles Erlichman. Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Cancer chemotherapy and pharmacology.
2015 Mar; 75(3):485-93. doi:
10.1007/s00280-014-2668-5. [PMID: 25556030] - Mehran Afshar, Jennifer Pascoe, Sue Whitmarsh, Nicholas James, Emilio Porfiri. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
Drug design, development and therapy.
2015; 9(?):13-9. doi:
10.2147/dddt.s73686. [PMID: 25552898] - Roberto Iacovelli, Antonella Palazzo, Patrizia Trenta, Silvia Mezi, Denise Pellegrino, Giuseppe Naso, Enrico Cortesi. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
American journal of clinical oncology.
2014 Dec; 37(6):611-5. doi:
10.1097/coc.0b013e31827de888. [PMID: 23388560] - James E Signorovitch, Nicholas J Vogelzang, Sumanta K Pal, Peggy L Lin, Daniel J George, Michael K Wong, Zhimei Liu, Xufang Wang, Ken Culver, Jeffrey A Scott, Eric Jonasch. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.
Current medical research and opinion.
2014 Nov; 30(11):2343-53. doi:
10.1185/03007995.2014.949645. [PMID: 25105304] - Lauren C Harshman, Nils Kroeger, Sun Young Rha, Frede Donskov, Lori Wood, Srinivas K Tantravahi, Ulka Vaishampayan, Brian I Rini, Jennifer Knox, Scott North, Scott Ernst, Takeshi Yuasa, Sandy Srinivas, Sumanta Pal, Daniel Y Heng, Toni K Choueiri. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Clinical genitourinary cancer.
2014 Oct; 12(5):335-40. doi:
10.1016/j.clgc.2014.03.003. [PMID: 24787966] - Philipp Ivanyi, Thomas Fuehner, Meike Adam, Christian Eichelberg, Edwin Herrmann, Axel Stuart Merseburger, Arnold Ganser, Viktor Grünwald. Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres.
Medical oncology (Northwood, London, England).
2014 Sep; 31(9):147. doi:
10.1007/s12032-014-0147-9. [PMID: 25134914] - Rana R McKay, Xun Lin, Julia J Perkins, Daniel Y C Heng, Ronit Simantov, Toni K Choueiri. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
European urology.
2014 Sep; 66(3):502-9. doi:
10.1016/j.eururo.2014.02.040. [PMID: 24613250] - Andres Jan Schrader, Sandra Seseke, Christian Keil, Edwin Herrmann, Peter J Goebell, Steffen Weikert, Sandra Steffens, Lothar Bergmann, Jan Roigas, Thomas Steiner. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer.
European urology.
2014 Aug; 66(2):275-81. doi:
10.1016/j.eururo.2013.08.055. [PMID: 24012472] - Joaquim Bellmunt, Francesc Pons, Abigail Foreshew, André P Fay, Thomas Powles, Camillo Porta, Sergio Bracarda, Megan E Lampron, Linda Cerbone, Cora N Sternberg, Thomas E Hutson, Toni K Choueiri. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Clinical genitourinary cancer.
2014 Aug; 12(4):262-9. doi:
10.1016/j.clgc.2014.03.002. [PMID: 24795159] - Reshma Rangwala, Yunyoung C Chang, Janice Hu, Kenneth M Algazy, Tracey L Evans, Leslie A Fecher, Lynn M Schuchter, Drew A Torigian, Jeffrey T Panosian, Andrea B Troxel, Kay-See Tan, Daniel F Heitjan, Angela M DeMichele, David J Vaughn, Maryann Redlinger, Abass Alavi, Jonathon Kaiser, Laura Pontiggia, Lisa E Davis, Peter J O'Dwyer, Ravi K Amaravadi. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Autophagy.
2014 Aug; 10(8):1391-402. doi:
10.4161/auto.29119. [PMID: 24991838] - F-X Nouhaud, J-D Rebibo, F Blanchard, J-C Sabourin, F Di Fiore, C Pfister. [Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
2014 Jul; 24(9):563-71. doi:
10.1016/j.purol.2013.12.001. [PMID: 24975791] - Satoshi Washino, Hitoshi Ando, Kentarou Ushijima, Keiko Hosohata, Masafumi Kumazaki, Naoko Mato, Yukihiko Sugiyama, Yutaka Kobayashi, Akio Fujimura, Tatsuo Morita. Temsirolimus induces surfactant lipid accumulation and lung inflammation in mice.
American journal of physiology. Lung cellular and molecular physiology.
2014 Jun; 306(12):L1117-28. doi:
10.1152/ajplung.00251.2013. [PMID: 24793166] - Thomas Grellety, Camille Brugères-Chakiba, Axel Chaminade, Guilhem Roubaud, Alain Ravaud, Marine Gross-Goupil. [Revision of therapeutic index for targeted treatment in kidney cancer: What if toxicity could predict efficacy?].
Bulletin du cancer.
2014 Jun; 101(6):608-18. doi:
10.1684/bdc.2014.1935. [PMID: 24977449]